|
WO2019116392A1
|
|
Therapeutic bacteriocins
|
|
US2020017843A1
|
|
Chimeric lysm polypeptides
|
|
US2019282673A1
|
|
Staphtame activity on biofilms
|
|
US2016199474A1
|
|
Incapacitated whole-cell immunogenic bacterial compositions produced by recombinant expression
|
|
WO2015145463A1
|
|
Phage-derived compositions for improved mycobacterial therapy
|
|
US2013273585A1
|
|
Soluble cytoplasmic expression of heterologous proteins in escherichia coli
|
|
MX2013011853A
|
|
Chimeric antibacterial polypeptides.
|
|
AU2009223632A1
|
|
Reducing conjugative plasmids in bacteria
|
|
EP2037946A2
|
|
Phage derived antimicrobial activities
|
|
US2007020240A1
|
|
Defined dose therapeutic phage
|
|
EP1560491A2
|
|
Bacteriophage having modified holin and uses thereof
|
|
US6896882B2
|
|
Lysin-deficient bacteriophages having reduced immunogenicity
|
|
MXPA04002866A
|
|
Incapacitated whole-cell immunogenic bacterial compositions.
|
